Abstract
Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.
References
Nov 15, 1997·Oncogene·A E MilnerC D Gregory
Mar 31, 1998·Oncogene·N ZamzamiG Kroemer
Jan 23, 1999·Oncogene·J C Reed
Apr 29, 1999·International Journal of Radiation Oncology, Biology, Physics·M D LogsdonT J McDonnell
Feb 17, 2000·Nature·A A AlizadehL M Staudt
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·I Lebedeva, C A Stein
Nov 9, 2001·Leukemia & Lymphoma·C PepperP Bentley
Oct 24, 2002·Blood·Guido MarcucciMichael A Caligiuri
Jan 11, 2003·Blood·Qun Liu, Yair Gazitt
Jan 17, 2003·Leukemia·N W C J van de DonkH M Lokhorst
Mar 15, 2003·Blood·Linda MileshkinH Miles Prince
Apr 30, 2003·Seminars in Oncology·Stanley R Frankel
May 24, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Yuan Zhang, Xiao Yong Lei
Jun 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A WunderlichUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Jun 26, 2003·The Journal of Biological Chemistry·Masato KatoDerek N J Hart
Jul 3, 2003·Bone Marrow Transplantation·M BenekliP L McCarthy
Oct 15, 2003·Clinical Lymphoma·Stephanie A GregoryAlan Saven
Dec 4, 2003·Cell Biology International·Y Zhang, W L Shen
Feb 1, 2002·Seminars in Oncology·Michael J KeatingMaher Albitar
Citations
Mar 17, 2005·World Journal of Urology·Alan SoColleen Nelson
May 17, 2005·Nitric Oxide : Biology and Chemistry·Karsten HemmrichVictoria Kolb-Bachofen
Apr 18, 2009·Leukemia & Lymphoma·Asher A Chanan-KhanSundar Jagannath
Jun 6, 2012·Hematology·Yong DingYuan Zhang
Aug 29, 2006·Oncogene·F HessN Cordes
May 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Elizabeth J MeredithJohn Gordon
May 27, 2017·Blood Cancer Journal·A PaulusA Chanan-Khan
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alessio NencioniAlberto Ballestrero